1[1]Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowing with simvastatin in 20536high-risk individuals: a randomized placebo-controlled trial.Lancet, 2002, 360:7-22.
2[2]Cox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation, 2004,109: Ⅱ 42- Ⅱ 48.
3[3]Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J,2003, 24: 225-248.
4[4]Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother, 2004, 38:110-118.
5[5]Horne BD, Muhlestein JB, Carlquist JF, et al. Intermountain Heart Collaborative (IHC) Study Group. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation, 2003,107: 258-263.
6[6]Gupta S. Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment? Int J Cardiol, 2004, 96:131-139.
7[7]Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 2005,352: 20-28.
8[8]Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy,LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 2005, 352:29-38.
9[9]Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol, 2000, 20: 556-562.
10[10]Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation, 2001, 103: 993-999.
